WO2015177805A1 - Combination of taurine and racemethionine for treatment of liver diseases - Google Patents
Combination of taurine and racemethionine for treatment of liver diseases Download PDFInfo
- Publication number
- WO2015177805A1 WO2015177805A1 PCT/IN2014/000510 IN2014000510W WO2015177805A1 WO 2015177805 A1 WO2015177805 A1 WO 2015177805A1 IN 2014000510 W IN2014000510 W IN 2014000510W WO 2015177805 A1 WO2015177805 A1 WO 2015177805A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- taurine
- add
- granules
- racemethionine
- rpm
- Prior art date
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title claims abstract description 174
- 229960003080 taurine Drugs 0.000 title claims abstract description 89
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 229940080308 racemethionine Drugs 0.000 title claims abstract description 47
- 208000019423 liver disease Diseases 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 65
- 239000008187 granular material Substances 0.000 claims abstract description 39
- 238000009472 formulation Methods 0.000 claims abstract description 17
- 239000003826 tablet Substances 0.000 claims abstract description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 239000006188 syrup Substances 0.000 claims abstract description 7
- 235000020357 syrup Nutrition 0.000 claims abstract description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 38
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 36
- 239000000463 material Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 23
- 235000019359 magnesium stearate Nutrition 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 13
- 239000011230 binding agent Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 10
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 10
- 239000008109 sodium starch glycolate Substances 0.000 claims description 10
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 10
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 9
- 238000007580 dry-mixing Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 229920002261 Corn starch Polymers 0.000 claims description 7
- -1 Crossprovidone Chemical compound 0.000 claims description 7
- 235000019759 Maize starch Nutrition 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 239000004408 titanium dioxide Substances 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 4
- 238000007906 compression Methods 0.000 claims description 4
- 230000006835 compression Effects 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 229960001375 lactose Drugs 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 238000003801 milling Methods 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 230000000717 retained effect Effects 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 239000011885 synergistic combination Substances 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 235000012222 talc Nutrition 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 claims description 3
- 229960003168 bronopol Drugs 0.000 claims description 3
- 238000005461 lubrication Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 claims description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 2
- 244000263375 Vanilla tahitensis Species 0.000 claims description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims description 2
- 238000005498 polishing Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000007963 capsule composition Substances 0.000 claims 1
- 230000001050 lubricating effect Effects 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 239000007916 tablet composition Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000000654 additive Substances 0.000 abstract description 2
- 230000002459 sustained effect Effects 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 42
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 34
- 229930182817 methionine Natural products 0.000 description 21
- 235000006109 methionine Nutrition 0.000 description 21
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 20
- 229960004452 methionine Drugs 0.000 description 20
- 239000003963 antioxidant agent Substances 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 229960003180 glutathione Drugs 0.000 description 17
- 108010024636 Glutathione Proteins 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 230000006378 damage Effects 0.000 description 15
- 235000006708 antioxidants Nutrition 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 12
- 238000001784 detoxification Methods 0.000 description 12
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 11
- 229960001570 ademetionine Drugs 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 208000019425 cirrhosis of liver Diseases 0.000 description 11
- 239000003440 toxic substance Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 210000005229 liver cell Anatomy 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 9
- 206010019708 Hepatic steatosis Diseases 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 230000003908 liver function Effects 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 231100000240 steatosis hepatitis Toxicity 0.000 description 8
- 208000004930 Fatty Liver Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 208000010706 fatty liver disease Diseases 0.000 description 7
- 231100000753 hepatic injury Toxicity 0.000 description 7
- 239000003053 toxin Substances 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 230000007882 cirrhosis Effects 0.000 description 6
- 230000009931 harmful effect Effects 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 230000009469 supplementation Effects 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 239000003613 bile acid Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003797 essential amino acid Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 229960005489 paracetamol Drugs 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 229960002433 cysteine Drugs 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000020776 essential amino acid Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229910001385 heavy metal Inorganic materials 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 231100000334 hepatotoxic Toxicity 0.000 description 4
- 230000003082 hepatotoxic effect Effects 0.000 description 4
- 231100000304 hepatotoxicity Toxicity 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 231100000167 toxic agent Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 239000004470 DL Methionine Substances 0.000 description 2
- 206010012444 Dermatitis diaper Diseases 0.000 description 2
- 208000003105 Diaper Rash Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 231100000481 chemical toxicant Toxicity 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 230000003212 lipotrophic effect Effects 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 231100000004 severe toxicity Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 125000004354 sulfur functional group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 230000007279 water homeostasis Effects 0.000 description 2
- 239000002676 xenobiotic agent Substances 0.000 description 2
- 230000002034 xenobiotic effect Effects 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- 238000002970 ATP quantitation Methods 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical class ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000031200 bile acid secretion Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 229940089491 hydroxycitric acid Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000426 osmoregulatory effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- IYPNVUSIMGAJFC-HLEJRKHJSA-M sodium;2-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)CC1 IYPNVUSIMGAJFC-HLEJRKHJSA-M 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000010891 toxic waste Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to a synergistic oral pharmaceutical composition for the effective treatment of liver diseases, the said composition comprises of main active ingredients such as Taurine and Racemethionine, along with pharmaceutically acceptable excipients.
- the liver is the heaviest and one of the largest organs in the body. Though this powerhouse organ is involved in over 500 different functions the major functions can be classified into two main categories:
- Liver plays a key role in maintaining body's chemical constitution and performs thousands of chemical reactions important in metabolism of major nutrients like carbohydrates, fats and proteins.
- Liver is the major organ responsible for the detoxification of internal as well as external toxic substances, infectious microbes, chemical substances, drugs, toxins as well alcoholic substances.
- l amino acids are commonly found in reduced levels. This leads to acute or chronic hepatotoxic conditions, hepatopathies and abnormal liver function tests mainly raised levels of alanine aminotransferase (ALT or SGPT) and aspartate aminotransferase (AST or SGOT).
- ALT or SGPT alanine aminotransferase
- AST or SGOT aspartate aminotransferase
- the present invention relates to health supplement food comprising branched chain amino acids composed of leucine (L), isoleucine (I) and valine (V) which is made to have a composition similar to essential amino acids contained in naturally-occurring milk, eggs, soybeans, beef etc, and enhancing instant impact power under anaerobic conditions, via addition of L- glutamine and taurine which are essentially required when a person is exposed to excessive exercise, stress or overwork; a health supplement food for improving a weak constitution, comprising herbal materials such as ginseng, red ginseng and Acanthppanax; and a diet food or beverage further comprising dietary fibres such as insulin, polydextrose and crystalline cellulose, and carnitine and hydroxy citric acid.
- L leucine
- I isoleucine
- V valine
- United States Patent 5817695 which describes of a nutritional product is provided for cancer patients, in terms of calorie requirement, a low concentration of carbohydrate, a high concentration of fat and an imbalance of amino acids wherein L-phenylalanine, L-tyrosine and L-methionine are present in the below normal concentrations and L-leucine is present in substantial excess of normal concentrations to suppress cancer growth and as an adjunct to conventional cancer therapies.
- Certain amino acids have found to play a promising role in preventing and treating a majority of these liver diseases due to their antitoxic, osmoregulatory effects and antioxidant properties. Glutathione and Taurine are vital amongst them.
- Racemethionine and taurine are such two important amino acids found to have synergistic therapeutic effect in normal liver functions as well as during stressed or toxic liver conditions hence the combination of those two active drugs have not been described or suggested in any prior art published documents.
- the pharmaceutically effective combination of Taurine and Racemethionine in the disclosed amount would effectively remove toxic chemicals and metabolites.
- a synergistic effective amount of present composition it enhances transport of important ions across hepatocytes thus improving their functions and recovery.
- a deficiency of taurine can lead to electrolyte imbalance due to impaired mineral transport across cell membranes and this reduces the ability of the liver to remove toxic substances.
- the present invention describes of a synergistic composition comprising of Taurine and Recemethionine wherein the active Taurine is being taken in the range of 250mg to 500mg and the Racemethionine is taken in the range of l Omg to 200mg by weight of the composition, the active weight resulting into a therapeutically , synergistically effective oral composition, in order to provide safe and effective oral dosage form along with other excipients.
- the invention is to provide different release drug profile such as sustained or controlled or retard formulation available in oral formulation (capsule, tablet, granules and syrup thereof)
- the present invention discloses an efficacious and synergistically effective pharmaceutical composition in oral dosage form.
- This comprises therapeutically effective amount of taurine taken in the range of 250mg to 500mg and the racemethionine is taken in the range of lOOmg to 200mg by weight of the composition along with recipients thereof unable to make the formulation stable, in the form of tablet, capsule, granules and syrup thereof.
- Liver is the main organ for taurine biosynthesis and also an important organ for taurine's many biological activities.
- Taurine a liver protecting amino acid, is essential for formation of bile acids and thus for detoxification processes.
- Further taurine contains sulfur and directly combines and removes of toxic chemicals and metabolites.
- the effective amount of Taurine reduces the secretion of apolipoprotein B100 and lipids in Hepatic G2 cells and is effective in removing fatty liver deposits, preventing liver disease, and reducing cirrhosis.
- taurine has protective and preventive role in portal hypertension, a detoxifying agent with antioxidant action that helps protect liver cells against various toxins.
- Taurine increases levels of antioxidant enzymes like glutathione peroxidase, superoxide dismutase and catalase in liver and thus protects hepatocytes from free radical and ROS induced damages.
- antioxidant enzymes like glutathione peroxidase, superoxide dismutase and catalase in liver and thus protects hepatocytes from free radical and ROS induced damages.
- Taurine deficiency and liver injuries wherein Taurine deficiency can trigger hepatitis and liver fibrosis, probably due to a diminished antioxidant defence, increase in inflammatory reactions and mitochondrial dysfunction in hepatocytes.
- taurine in combination of recemethionin in a liver supplementation is beneficial for the treatment of above complication.
- Racemethionine in combination of taurine at the effective amount is anti-oxidant amino acid useful to treat liver diseases caused by alcoholism including cirrhosis. It protects hepatocytes and enhances their regeneration thus improving liver functions. It acts as important sulphur and methyl group donor in detoxification reactions in liver cells. Apart from direct beneficial actions Racemethionine is a major source of other liver detoxificants including glutathione and S-Adenosyl Methionine (SAMe).
- SAMe S-Adenosyl Methionine
- racemethionine is Sulphur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals. Other commonly used names are methionine and DL -methionine.
- Racemethionine (race-e-me-THYE-oh ' -neen) is used to make the urine more acidic. Making the urine more acidic helps to relieve skin irritation in incontinent (loss of bladder control) adults and diaper rash in infants. This medicine also helps to control strong urine odor. Racemethionine produces ammonia-free urine by lowering the urinary pH.
- Racemethionine is for treating hepatic injury due to acetaminophen overdose.
- Racemethionine and Taurine protect against acetaminophen overdose-induced hepatotoxicity by maintaining or restoring hepatic concentrations of glutathione.
- Glutathione is required to inactivate an intermediate metabolite of acetaminophen, which is hepatotoxic.
- excessive quantities of this metabolite are formed because the primary metabolic pathways (glucuronide and sulfate conjugation) become saturated.
- the excess metabolite binds irreversibly to essential hepatic proteins and enzymes, causing cell damage and death.
- Racemethionine serves as a precursor for the synthesis of glutathione and sulphate.
- Taurine or 2-aminoethanesulfonic acid, is an organic acid. It is a major constituent of bile and can be found in the large intestine and in the tissues of many animals, including humans. Taurine is the most abundant free amino acid in the human body. It has a ubiquitous distribution and accounts for approximately 0.1% of total body weight. Taurine has many fundamental biological roles such as conjugation of bile acids, antioxidation, osmoregulation, membrane stabilization and modulation of calcium signaling.
- Taurine is conjugated via its amino terminal group with chenodeoxycholic acid and cholic acid to form the bile salts sodium taurochenodeoxycholate and sodium taurocholate.
- the low pKa of taurine's sulfonic acid group ensures this moiety is negatively charged in the pH ranges normally found in the intestinal tract and, thus, improves the surfactant properties of the cholic acid conjugate, it has been shown to be effective in removing fatty liver deposits in rats, preventing liver disease, and reducing cirrhosis in tested animals.
- taurine reacts with and neutralizes hypochlorous acid, which is generated during oxidative neutrophil burst.
- the result is a stable taurochloramine compound, as opposed to unstable aldehyde compounds formed in states of taurine deficiency.
- Individuals who are taurine deficient may become more susceptible to tissue damage by xenobiotic agents such as aldehydes, chlorine, and certain amines.
- Animal studies have also demonstrated taurine's ability to complex with and neutralize the xenobiotic effects of carbon tetrachloride and retinol. Research also suggests that translocation of bacterial endotoxins may be a factor in determining a person's response to xenobiotic insult.
- endotoxin markedly enhance liver injury from hepatotoxic substances such as carbon tetrachloride, ethanol, and cadmium. Taurine was found to significantly inhibit intestinal endotoxin translocation and subsequently decrease hepatic injury from these substances.
- racemethionine is Sulphur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals. Other commonly used names are methionine and DL -methionine.
- Racemethionine (race-e-me-THYE-oh-neen) is used to make the urine more acidic. Making the urine more acidic helps, to relieve skin irritation in incontinent (loss of bladder control) adults and diaper rash in infants. This medicine also helps to control strong urine odor. Racemethionine produces ammonia-free urine by lowering the urinary pH.
- Racemethionine is for treating hepatic injury due to acetaminophen overdose.
- the present formulation containing the combination of taurine and racemethionine in an effective amount has prevented the above disclosed diseases effectively the said comprising an effective amount of taurine in the range of 250mg to 500mg, and recemethionine in the range of lOOmg to 200mg , excipients used in the present invention taken from maize starch 50 mg to 75mg, lactose 44mg to 66mg , microcrystalline cellulose taken in the range of 60mg to 90mg, colloidal silicone dioxide lOmg to 15mg, poly vinyl pyrrolidine 12mg to 18mg, isopropyl alcohol 90mg to 135mg, sodium starch glycolate 5mg to 7.5 mg , crosspovidene4mg to 6mg, magnesium stearate lOmg to I5mg, purified talc 5mg to 7,5mg, hydroxypropyl methyl cellulose l lmg , titanium dioxide 2, isopropyl alcohol 97mg,
- a method for the preparation of above formulation comprising the following steps:
- the method for preparation of tablet comprising the following steps- 1. Take taurine shift it 40 # then add in mass mixture.
- step (5) solution slowly in mass mixture with mixing till proper mass obtain.
- the method for preparation of capsule comprising the following steps-
- the method for preparation of Granules comprising the following steps- Dispensing:
- liver performs the important function of detoxification of externally introduced toxic substances as well as internally produced toxic waste substances. These functions are carried out either physically by filtering the blood and removing the Waste substances or by neutralizing them chemically.
- the process involves the formation and utilization of thousands of chemicals including enzymes and the stepwise detoxification where the substances are converted into less harmful and more soluble substrates which are easily excreted out of body via urine or other excretory organs.
- These functions require continuous administration of amino acids including racemethionine and taurine.
- liver itself is under the danger of severe toxicities and damages due to harmful toxins, waste products, viruses, bacteria or alcohol. In normal circumstances the liver is protected from their harmful effects due to following two ways:
- liver enzymes like SCOT (AST) or SGPT (ALT)
- Alcohol is a major liver toxicant and its chronic consumption may cause following types of liver damages:
- Fat accumulation (fatty liver or steatosis): In some people, the liver is enlarged, tender, or both.
- Inflammation alcoholic hepatitis: People may have a fever, jaundice, fatigue, under nutrition, and a tender, painful, enlarged liver.
- Viruses are also the major culprits for liver diseases including hepatitis. Racemethionine and taurine formulation in Hepatoprotection :
- the best way to protect the liver is to provide the basic building blocks to support its functions or to increase the antioxidant defence that protects the liver cells against toxic damages.
- Certain amino acids have found to play important role in these vital functions, racemethionine and Taurine are the two major amongst them.
- racemethionine sulfur containing lipotropic amino acid in hepatoprotection has been amply supported. It is a potent methyl donor, powerful antioxidant and a major source of other liver detoxificants including glutathione and S-Adenosyl Methionine (SAMe). Further methionine is the precursor for the synthesis of cysteine and taurine required in large quantities for liver functions.
- Racemethionine has following important functions:
- Methionine acts as a chelator, binding to heavy metals such as lead and others and removing them from the body before they can build up and cause damage to tissues. Methionine also protects liver from the damaging effects of drugs like acetaminophen, nimesulide and other hapatotoxic drugs.
- Methionine reconstitutes an important antioxidant defence mechanism. It neutralizes a variety of oxidants by forming methionine sulfoxide and thus scavenges free radicals like H 2 0 2, superoxide, ozone, hypochlorous acid, and chloramines,
- Alcohol is a major cause of liver disease that disrupts methionine and oxidative balance.
- Methionine supplementation was found to improve the alcohol-induced histological changes in the liver.
- Triglyceride content of the liver was found to decrease in a dose-dependent manner with increasing methionine ingestion.
- Hepatic adenosine triphosphate content increased significantly with higher methionine consumption.
- Methionine is the major precursor for other important antioxidant substances like SAMe, cysteine and glutathione.
- SAM S-adenosyl-L-methiottine
- SAMe improves and normalizes liver function. In Europe, SAMe is used in the treatment of cirrhosis and liver damage caused by alcohol.
- SAMe increases membrane fluidity, restoring several factors that promote bile flow.
- Treatment with SAMe helps decrease serum bilirubin (pigment in the blood that can cause jaundice) in patients with elevated serum bilirubin level.
- SAMe was also shown to be useful for opposing the oxidative stress and the alcohol-induced liver injury.
- Glutathione (GSH) - The Master Antioxidant in liver: Glutathione is an antioxidant often referred to as the body's "master antioxidant” due to its central role in protecting the body's cells from free radical damage. Glutathione is composed of the amino acids cysteine (formed from methionine), glutamine and glycine and is concentrated in the liver.
- glutathione Due to its -SH group, glutathione controls many redox reactions. In liver cells, glutathione protects hepatOcytes from the damaging effects of free radicals, toxins, heavy metals and hepatotoxic drugs.
- liver enzyme like SGOT and SGPT.
- Glutathione is important in the management of patients with alcoholic liver disease and viral hepatitis, particularly those with hepatitis C.
- Glutathione protects cells in several ways. It neutralizes oxygen molecules before tney can harm cells. It forms the enzyme glutathione peroxidase which neutralizes hydrogen peroxide. It is also a component of another antioxidant enzyme, glutathione-S-transferase which is a broad-spectrum liver-detoxifying enzyme.
- Taurine (2-aminoethanesulfonic acid) is a sulfur-containing conditionally-essential amino acid. Derived from methionine and cysteine metabolism, taurine is known to play an important role in numerous physiological functions. Apart from conjugation of bile acids, other metabolic actions of taurine include: detoxification, membrane stabilization, osmoregulation, and modulation of cellular calcium levels. It is found in high concentrations in skeletal muscles, central nervous system as well as in the heart muscles and liver. Taurine is incorporated into one of the most abundant bile acids, chenodeoxychloic acid. Studies have shown that taurine deficiency results in reduced bile acid secretion, reduced fat absorption and reduced liver function, all of which can be reversed by supplementing the diet with taurine.
- Detoxifying effects -Taurine directly combines with toxic molecules and removes them from blood circulation. Thus it helps in blood purification that protects important organs including liver from damages.
- Taurine in inflammatory liver cells has cytoprotective action. Taurine increases the activities of antioxidant enzymes like superoxide dismutase, glutathione peroxidase and catalase. Taurine reduces Reactive Oxygen Species (ROS) levels by increasing the levels of the antioxidant enzymes.
- ROS Reactive Oxygen Species
- Taurine is effective in removing fatty liver deposits, preventing liver disease, and reducing cirrhosis. Importantly taurine has protective and preventive role in portal hypertension, the major cause of death in cirrhotic liver conditions.
- taurine supplementation has been shown to reduce bilirubin, total bile acids, and biliary glycine taurine ratio which are important indicators of liver toxicities.
- Taurine plays important role in alcoholic liver disorders. Taurine reverses the hepatic steatosis (deposition of fat) and lipid peroxidation caused by chronic alcohol consumption.
- Racemethionine and Taurine are concentrated in liver and play important role in liver function, detoxification of harmful substances and hepatocyte protection. Many of their functions are independent of each other.
- taurine When taurine is used up for metabolic reactions, it is biosynthesized from methionine. Thus methionine is used up in this process and can become deficient in cells during increased workload. Supplementation of taurine reduces the need for conversion of methionine to taurine thus allowing Methionine for its other important functions of liver protection. Further, in some patients excess methionine has been reported to increase homocysteine levels. It is found that taurine causes excretion of homocysteine via kidney and thus balances the effect on homocysteine, if any.
- racemethionine and Taurine is a synergistic combination useful in various liver diseases and others.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention describes of a synergistic oral composition comprising of taurine and racemethionine, wherein the taurine being taken in the range of 250mg to 500mg and the racemethionine is taken in the range of lOOmg to 200mg by weight of the Composition, the active weight resulting into a therapeutically, synergisticaily effective oral composition, in order to provide safe and effective dosage form along with other pharmaceutical excipients. It provide different release drug profile such as Sustained or controlled or retard formulation available in oral formulation (capsule, tablet, granules and syrup thereof) and instant energy with hepatic disorders, active antioxidant properties, due to its synergisticaily effective amount of taurine and racemethionine in the formulation, the effective amount as above is taken along with suitable excipients, additives and releasing agents to make a formulation.
Description
COMBINATION OF TAURINE AND RACEMETHIONINE FOR
TREATMENT OF LIVER DISEASES
FIELD OF THE INVENTION
The present invention relates to a synergistic oral pharmaceutical composition for the effective treatment of liver diseases, the said composition comprises of main active ingredients such as Taurine and Racemethionine, along with pharmaceutically acceptable excipients.
BACKGROUND OF THE INVENTION
The back ground and field of the invention related to a synergistic oral pharmaceutical composition for treatment of liver diseases, the formulation made by combination of taurine and recemethionine as active ingredients' whereas the none of the prior art related to the taurine and recemethionine combination not been disclosed
The liver is the heaviest and one of the largest organs in the body. Though this powerhouse organ is involved in over 500 different functions the major functions can be classified into two main categories:
- Metabolic functions: Liver plays a key role in maintaining body's chemical constitution and performs thousands of chemical reactions important in metabolism of major nutrients like carbohydrates, fats and proteins.
- Detoxification: Liver is the major organ responsible for the detoxification of internal as well as external toxic substances, infectious microbes, chemical substances, drugs, toxins as well alcoholic substances.
These important functions are possible due to of chemical reactions which are controlled by enzymes - the protein substances made up of amino acids. Certain amino acids are concentrated in liver and are responsible for major reactions in liver like methylation, sulfuration and so on. During stressed liver conditions like in alcoholism, fatty liver or in toxic liver diseases these
l
amino acids are commonly found in reduced levels. This leads to acute or chronic hepatotoxic conditions, hepatopathies and abnormal liver function tests mainly raised levels of alanine aminotransferase (ALT or SGPT) and aspartate aminotransferase (AST or SGOT).
Supplementation of these important amino acids helps in maintaining the proper liver functions, protecting the liver Cells from toxic damages and in many cases in regeneration of liver cells in necrotic region. The prior published WO 2006/062273 Al, teaches to a health supplement food utilizing, in particular, branched amino acids from among essential amino acids. More specifically, the present invention relates to health supplement food comprising branched chain amino acids composed of leucine (L), isoleucine (I) and valine (V) which is made to have a composition similar to essential amino acids contained in naturally-occurring milk, eggs, soybeans, beef etc, and enhancing instant impact power under anaerobic conditions, via addition of L- glutamine and taurine which are essentially required when a person is exposed to excessive exercise, stress or overwork; a health supplement food for improving a weak constitution, comprising herbal materials such as ginseng, red ginseng and Acanthppanax; and a diet food or beverage further comprising dietary fibres such as insulin, polydextrose and crystalline cellulose, and carnitine and hydroxy citric acid.
United States Patent 5817695 which describes of a nutritional product is provided for cancer patients, in terms of calorie requirement, a low concentration of carbohydrate, a high concentration of fat and an imbalance of amino acids wherein L-phenylalanine, L-tyrosine and L-methionine are present in the below normal concentrations and L-leucine is present in substantial excess of normal concentrations to suppress cancer growth and as an adjunct to conventional cancer therapies.
Certain amino acids have found to play a promising role in preventing and treating a majority of these liver diseases due to their antitoxic, osmoregulatory effects and antioxidant properties. Glutathione and Taurine are vital amongst them.
Racemethionine and taurine are such two important amino acids found to have synergistic therapeutic effect in normal liver functions as well as during stressed or toxic liver conditions
hence the combination of those two active drugs have not been described or suggested in any prior art published documents.
OBJECTS
The pharmaceutically effective combination of Taurine and Racemethionine in the disclosed amount would effectively remove toxic chemicals and metabolites.
A synergistic effective amount of present composition it enhances transport of important ions across hepatocytes thus improving their functions and recovery. A deficiency of taurine can lead to electrolyte imbalance due to impaired mineral transport across cell membranes and this reduces the ability of the liver to remove toxic substances.
SUMMARY OF THE INVENTION
The present invention describes of a synergistic composition comprising of Taurine and Recemethionine wherein the active Taurine is being taken in the range of 250mg to 500mg and the Racemethionine is taken in the range of l Omg to 200mg by weight of the composition, the active weight resulting into a therapeutically , synergistically effective oral composition, in order to provide safe and effective oral dosage form along with other excipients.
In one aspect, the invention is to provide different release drug profile such as sustained or controlled or retard formulation available in oral formulation (capsule, tablet, granules and syrup thereof)
In one aspect, it will provide instant energy with hepatic disorders and active antioxidant properties, due to its synergistically effective amount of taurine and recemethionine in the oral formulation, the effective amount as above is taken along with suitable excipients, additives and releasing agents to make a formulation.
DETAILED DESCRIPTION OF THE INVENTION
The present inversion described in detail in connection with certain preferred ,and optional embodiments. Alleged composition surprisingly found the synergistic combination of active ingredients such as taurine and racemethionine in an effective amouilt for the treatment of liver diseases.
The present invention discloses an efficacious and synergistically effective pharmaceutical composition in oral dosage form. This comprises therapeutically effective amount of taurine taken in the range of 250mg to 500mg and the racemethionine is taken in the range of lOOmg to 200mg by weight of the composition along with recipients thereof unable to make the formulation stable, in the form of tablet, capsule, granules and syrup thereof.
Further embodiment of the invention, Liver is the main organ for taurine biosynthesis and also an important organ for taurine's many biological activities. Taurine a liver protecting amino acid, is essential for formation of bile acids and thus for detoxification processes. Further taurine contains sulfur and directly combines and removes of toxic chemicals and metabolites. The effective amount of Taurine reduces the secretion of apolipoprotein B100 and lipids in Hepatic G2 cells and is effective in removing fatty liver deposits, preventing liver disease, and reducing cirrhosis. Importantly taurine has protective and preventive role in portal hypertension, a detoxifying agent with antioxidant action that helps protect liver cells against various toxins. Taurine increases levels of antioxidant enzymes like glutathione peroxidase, superoxide dismutase and catalase in liver and thus protects hepatocytes from free radical and ROS induced damages. In the case of Taurine deficiency and liver injuries (study on mice) wherein Taurine deficiency can trigger hepatitis and liver fibrosis, probably due to a diminished antioxidant defence, increase in inflammatory reactions and mitochondrial dysfunction in hepatocytes.
The inclusion of taurine in combination of recemethionin in a liver supplementation is beneficial for the treatment of above complication.
Liver injuries (study on mice) wherein Taurine deficiency can trigger hepatitis and liver fibrosis, probably due to a diminished antioxidant defence, increase in inflammatory reactions and mitochondrial dysfunction in hepatocytes is being demonstrated and the deficiency is being recovered using the inventive composition.
As the deficiency increases free radicals, ROS mediated oxidative damages and formation of toxic metabolites in liver cells. This can be seen as there is a 6-fold increase in the TNF plasma levels. Tissue necotising factor alpha is a marker for inflammatory processes that leads to cell death. The present invention supplementation prevents these damages and protects cells.
Severe toxicities cause death of more and more hepatocytes. These cells are replaced by formation of new cells. If the cell destruction is high, the newly formed cells are immature and abnormal in shape (oval shape). Development of these cells is associated with liver dysfunction, which can be protected and recovered by using the alleged composition.
This affectivity of the alleged composition is observed in a rat study which used carbon tetrachloride as toxicant. The alleged composition pre-treatment induced a marked beneficial effect regarding the prevention of hepatocellular necrosis and atrophy as demonstrated morphologically. In conclusion, these results suggest that pre-treatment prevents the morphologic damage caused by CC14 in the early stages.
In embodiment of the invention Racemethionine in combination of taurine at the effective amount, is anti-oxidant amino acid useful to treat liver diseases caused by alcoholism including cirrhosis. It protects hepatocytes and enhances their regeneration thus improving liver functions. It acts as important sulphur and methyl group donor in detoxification reactions in liver cells. Apart from direct beneficial actions Racemethionine is a major source of other liver detoxificants including glutathione and S-Adenosyl Methionine (SAMe).
The racemethionine is Sulphur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals. Other commonly used names are methionine and DL -methionine.
The first indication of Racemethionine (race-e-me-THYE-oh'-neen) is used to make the urine more acidic. Making the urine more acidic helps to relieve skin irritation in incontinent (loss of bladder control) adults and diaper rash in infants. This medicine also helps to control strong urine odor. Racemethionine produces ammonia-free urine by lowering the urinary pH.
But one more very important function which is exhibited by Racemethionine is for treating hepatic injury due to acetaminophen overdose.
Mechanism of action
Racemethionine and Taurine protect against acetaminophen overdose-induced hepatotoxicity by maintaining or restoring hepatic concentrations of glutathione. Glutathione is required to inactivate an intermediate metabolite of acetaminophen, which is hepatotoxic. In acetaminophen overdose, excessive quantities of this metabolite are formed because the primary metabolic pathways (glucuronide and sulfate conjugation) become saturated. The excess metabolite binds irreversibly to essential hepatic proteins and enzymes, causing cell damage and death. Racemethionine serves as a precursor for the synthesis of glutathione and sulphate.
The Combined effect in hepatic disorders
Taurine, or 2-aminoethanesulfonic acid, is an organic acid. It is a major constituent of bile and can be found in the large intestine and in the tissues of many animals, including humans. Taurine is the most abundant free amino acid in the human body. It has a ubiquitous distribution and accounts for approximately 0.1% of total body weight. Taurine has many fundamental biological roles such as conjugation of bile acids, antioxidation, osmoregulation, membrane stabilization and modulation of calcium signaling.
Taurine is conjugated via its amino terminal group with chenodeoxycholic acid and cholic acid to form the bile salts sodium taurochenodeoxycholate and sodium taurocholate. The low pKa of taurine's sulfonic acid group ensures this moiety is negatively charged in the pH ranges normally found in the intestinal tract and, thus, improves the surfactant properties of the cholic acid conjugate, it has been shown to be effective in removing fatty liver deposits in rats, preventing liver disease, and reducing cirrhosis in tested animals.
Mode of action
The present invention and it's mode of action which demonstrated that taurine reacts with and neutralizes hypochlorous acid, which is generated during oxidative neutrophil burst. The result is a stable taurochloramine compound, as opposed to unstable aldehyde compounds formed in states of taurine deficiency. Individuals who are taurine deficient may become more susceptible to tissue damage by xenobiotic agents such as aldehydes, chlorine, and certain amines. Animal
studies have also demonstrated taurine's ability to complex with and neutralize the xenobiotic effects of carbon tetrachloride and retinol. Research also suggests that translocation of bacterial endotoxins may be a factor in determining a person's response to xenobiotic insult. Even small amounts of endotoxin markedly enhance liver injury from hepatotoxic substances such as carbon tetrachloride, ethanol, and cadmium. Taurine was found to significantly inhibit intestinal endotoxin translocation and subsequently decrease hepatic injury from these substances.
The racemethionine is Sulphur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals. Other commonly used names are methionine and DL -methionine.
The first indication of Racemethionine (race-e-me-THYE-oh-neen) is used to make the urine more acidic. Making the urine more acidic helps, to relieve skin irritation in incontinent (loss of bladder control) adults and diaper rash in infants. This medicine also helps to control strong urine odor. Racemethionine produces ammonia-free urine by lowering the urinary pH.
But one more very important function which is exhibited by Racemethionine is for treating hepatic injury due to acetaminophen overdose.
The present formulation containing the combination of taurine and racemethionine in an effective amount has prevented the above disclosed diseases effectively the said comprising an effective amount of taurine in the range of 250mg to 500mg, and recemethionine in the range of lOOmg to 200mg , excipients used in the present invention taken from maize starch 50 mg to 75mg, lactose 44mg to 66mg , microcrystalline cellulose taken in the range of 60mg to 90mg, colloidal silicone dioxide lOmg to 15mg, poly vinyl pyrrolidine 12mg to 18mg, isopropyl alcohol 90mg to 135mg, sodium starch glycolate 5mg to 7.5 mg , crosspovidene4mg to 6mg, magnesium stearate lOmg to I5mg, purified talc 5mg to 7,5mg, hydroxypropyl methyl cellulose l lmg , titanium dioxide 2, isopropyl alcohol 97mg, methylene chloride 146mg, and Sucrose 500mg to 750mg, Sorbitol 2000mg to 3250mg, Citric acid 5mg to 7.5mg, SMP 5mg to 7.5mg, SPP lrrig to 7.5mg, Bronopol 1.25mg to 2.50mg, Citric acid 1.25mg to 2.50mg, Sodium CMC lOmg to 35mg, Sodium benzoate lOmg to 35mg, Water, Colour & essence taken for preparing tablets, capsules, Granules & syrup.
The above combination has been exemplified with working examples
A method for the preparation of above formulation comprising the following steps:
Dispensing:
• Taking all the raw materials to be used for the process must be approved prior to start of dispensing.
• Check the weighing balance calibrated or not and clean the dispensing utilities.
• Check temperature, relative humidity and pressure differential of dispensing area within the limits.
• Weigh the active and excipients as per requisition.
• All the raw materials are then packed in individual poly bags with dispensing Label and containers with proper status label.
• „ The dispensed materials to be transferred to the dispensing hold.
• The raw material is then transferred to the processing area when required i.e., when batch manufacturing is undertaken.
Sifting:
• Sift separately required quantities of Taurine, Racemethionine, Maize Starch, Lactose, Microcrystalline Cellulose, Colloidal silicon Dioxide and collect each in a individual double lined polybag.
Dry Mixing
• Load the sifted Materials in Rapid Mixer Granulator (RMG) and mix for 15 minutes at
100 RPM.
Binder Preparation
• In a Clean S.S. vessel, prepare binder solution with Polyvinyl Pyrrolidone (PVPK-30) and Isopropyl Alcohol by continuous stirring to get uniform Paste.
Granulation
• After Completion of dry mixing, start to add binder solution in RMG with impeller at 75 RPM and chopper off for 5 minute. Stop RMG and rake the stick material on RMG inner wall and Impeller.
• Close the lid of RMG and start mixing speed at 75 RP^M and chopper off for 05 minutes to make lumps of resulting materials. Then allow mixing by running impeller at 75 RPM and chopper on for 2 minute to prepare granules.
Drying
• Air dry the wet mass in fluidized bed dryer for 05 minutes.
• Dry material at an inlet air temperature of 60°C ± 5°C.
• Rake the material after completion of each drying cycle.
• Continue dry the granules till LOD of the granules achieved between NMT 5.0 % w/w at 105°C.
Sifting and Milling
• Sift the dried granules through sieve 16 # (SS) and collect the granules in cleaned container lined with polybag.
• Mill the oversized Granules retained on sieve through 1.2 mm SS screen with forward direction at 1500 RPM. Collect the milled granules in cleaned container line with polybag.
Blending and Lubrication:
• Sift separately Purified Talc, Magnesium Stearate, Sodium Starch Glycolate, and Crossprovidone and through Sieve 60 # and collect in a double lined polybag.
• Transfer the dried sifted and milled granules of above stage in to Octagonal Blender and add above sifted lubricant materials (Sodium Starch Glycolate & Purified Talc, Crossprovidone, Magnesium Stearate) in to octagonal blender. Close the lid of blender and run it for 15 min at 15 RPM.
• Add sifted Magnesium Stearate of above stage to octagonal blender. Close the lid of blender and run 3 minutes at 15 RPM.
Compression:
• Compress the lubricated blend using tablet shaped punches by compression machine. Coating:
(A) Preparation Of Coating Solution
• In S.S. vessel transfer required quantities of Hydroxy Propyl Methyl Cellulose, Titanium Dioxide adds Isopropyl Alcohol, Methylene Chloride with continuous stirring to prepare the slurry.
• Transfer the solution to solution tank and use for coating purpose.
(B) Coating Instruction And Operation
• Load the tablets into Pearl Coater Switch on the hot air blower. Adjust the temperature of incoming air to 50°C- 55°C. Start rotation of coating pan and spray the dispersion.
• Continue coating until entire coating dispersion is used.
• Store the coated Tablets in double Polylined Container with tight fitting lids; label the Containers with all relevant Batch details.
The method for preparation of tablet comprising the following steps-
1. Take taurine shift it 40 # then add in mass mixture.
2. Take racemethionine shift it 40 # then add in mass mixture.
3. Take lactose shift it 40 # then add in mass mixture.
4. Take starch shift it 40 # then add in mass mixture.
5. Take LP. A then add in mass mixture mix it for 30 minutes.
6. Take P.V.P.K30 8with contains stirring till (clear soon)
7. Add step (5) solution slowly in mass mixture with mixing till proper mass obtain.
8. Shift above mass through 8# in multi mill.
9. Keep it in tray drayer.
10. Adjust temp at 40 c for 4 hours till LP. A complete remove then heat it 60 c for two hours.
11. Shift it at 16 # through shifter.
12. Pass magnesium stearate and talcum mix it and shift it through 100#
13. Mix step 11 & 12 in mass mixture for 5 minutes.
14. Compress the tablet.
In process
1. Check D.T. limit.
2. Check thickness limit.
3. Check weight individual tab for every two hours.
The method for preparation of capsule comprising the following steps-
1. Take 5 kg and taurine shift it 40 # through shifter.
2. Take 2 kg racemethionine shift it 40 # through shifter.
3. Take Magnesium Stearate 0.030 kg shift it 100 # through shifter.
4. Take talcum 0.020 kg shift it 100 # through shifter.
5. Mix it add material and mixture it for 30 minutes
6. Check cap filling machine.
7. Fill 300 cap plates with cap.
8. Fill it with powder 223gms for 300 cap. In process
1. Check 300 filled capsule
a) Proper sealing
b) Denting
c) Locking
2. 20 cap individual cap weight limit +/- 3%
3. 20 cap weight limit +/- 2%
4. DT not more than 10 minutes.
5. Polishing
6. Striping
The method for preparation of Granules comprising the following steps- Dispensing:
• Weigh the active and excipients as per requisition.
• All the raw materials are then packed in individual poly bags with dispensing Label and containers with proper status label.
• The dispensed materials to be transferred to the dispensing hold.
• The raw material is then transferred to the processing area when required i.e., when batch manufacturing is undertaken.
Sifting:
• Sift separately required quantities of Taurine, Racemethionine, Maize Starch, Lactose, Microcrystalline Cellulose, Colloidal silicon Dioxide and collect each in an individual double lined polybag.
Dry Mixing
• Load the sifted Materials in Rapid Mixer Granulator (RMG) and mix for 15 minute at
100 RPM.
Binder Preparation
• In a Clean S.S. vessel, prepare binder solution with Polyvinyl Pyrrolidone (PVPK-30) and Isopropyl Alcohol by continuous stirring to get uniform Paste.
Granulation
• After Completion of dry mixing, start to add binder solution in RMG with impeller at 75 RPM and chopper off for 5 minute. Stop RMG and rake the stick material on RMG inner wall and Impeller.
• Close the lid of RMG and start mixing speed at 75 RPM and chopper off for 05 minutes to make lumps of resulting materials. Then allow mixing by running impeller at 75 RPM and chopper on for 2 minute to prepare granules.
Drying
• Air dry the wet mass in fluidized bed dryer for 05 minutes.
• Dry material at an inlet air temperature of 60°C ± 5°C
• Rake the material after completion of each drying cycle.
• Continue dry the granules till LOD of the granules achieved between NMT 5.0 %
w/w at 105°C.
Sifting and Milling
• Sift the dried granules through sieve 16 # (SS) and collect the granules in cleaned container lined with polybag,
• Mill the oversized Granules retained on sieve through 1.2 mm SS screen with forward direction at 1500 RPM. Collect the milled granules in cleaned container line with polybag.
Blending and Lubrication:
• Sift separately Purified Talc, Magnesium Stearate, Sodium Starch Glycolate^ and Crossprovidone and through Sieve 60 # and collect in a double lined polybag.
• Transfer the dried sifted and milled granules of above stage iii to Octagonal Blender and add above sifted lubricant materials (Sodium Starch Glycolate & Purified Talc, Crossprovidone, Magnesium Stearate) in to octagonal blender. Close the lid of blender and run it for 15 min at 15 RPM,
• Add sifted Magnesium Stearate of above stage to octagonal blender. Close the lid of blender and run 3 minutes at 15 RPM.
The method for preparation of syrup comprising the following steps-
1. Take 20 litres D. M. water heat at 20° C than add sucrose with continuous stirring till complete sucrose dissolve.
2. Add SMP 0.100 kg, SPP 0.020 kg, sodium banzoate 0.100 kg bronopol, 0.025kg with continuous CMC sodium 0.200 kg and citric acid 0.100 kg.
3. Then heat it to boil.
4. Add sorbitol 20 litters with stirring.
5. Fill it then keep it at room temperature.
6. Dissolve L- Taurine 6.750kg in DM water stirring till complete dissolve then filter it and add it in main tank.
7. Dissolve racemethionine 2.500kg in 10 litter DM water stirring till complete dissolve then filter it and add it in main tank.
8. Dissolve colour tetrazine yellow 10 gm in 5 litter DM water stirring till complete dissolve then filter it and add it in main tank.
9. Dissolve essence chocolate bourbon 300 ml and essence vanilla 30 ml and essence honey 20 ml mix it and add in main tank.
10. Complete volume 100 litter by adding DM water.
11. Adjust pH 4.00 to 5.00.
12. Filter complete volume and keep it With label. Ready for filling
Demonstration with regard to synergism, and affectivity of the composition
Apart from metabolic functions liver performs the important function of detoxification of externally introduced toxic substances as well as internally produced toxic waste substances. These functions are carried out either physically by filtering the blood and removing the Waste substances or by neutralizing them chemically. The process involves the formation and utilization of thousands of chemicals including enzymes and the stepwise detoxification where the substances are converted into less harmful and more soluble substrates which are easily excreted out of body via urine or other excretory organs. These functions require continuous administration of amino acids including racemethionine and taurine.
While doing these important function, Liver itself is under the danger of severe toxicities and damages due to harmful toxins, waste products, viruses, bacteria or alcohol. In normal circumstances the liver is protected from their harmful effects due to following two ways:
1. Directly acting and neutralizing the toxic substances: This process involves the transfer of methyl or sulfur group to the toxic substance or its metabolite making them less harmful, racemethionine and taurine both are the excellent sources of methyl group whereas taurine is the richest source of sulfur group in detoxification processes. Further taurine is the most abundant amino acid present in bile which has important role in fat metabolism and detoxification process.
2. The presence of antioxidants which destroy the harmful free radicals and neutralize then! before they could cause serious damage. Glutathione formed from racemethionine is the major antioxidant in the liver.
When body's detoxification process is weakened or the burden of waste and toxic substances increases, the normal detoxification process is insufficient making liver more prone for physical and chemical damages which include:
- Increase in liver size (enlarged liver)
- Accumulation of fats in liver (fatty liver)
- Liver structure damage which can be confirmed by increased blood, levels of liver enzymes like SCOT (AST) or SGPT (ALT)
- Replacement of normal liver cells with abnormal liver cells and liver fibrosis
- Reduced liver function causing increased toxicities to liver itself, rising levels of these toxicants in blood damages Other organs like kidneys, brain or heart.
Alcohol is a major liver toxicant and its chronic consumption may cause following types of liver damages:
• Fat accumulation (fatty liver or steatosis): In some people, the liver is enlarged, tender, or both.
• Inflammation (alcoholic hepatitis): People may have a fever, jaundice, fatigue, under nutrition, and a tender, painful, enlarged liver.
• Liver fibrosis
• Cirrhosis
Viruses are also the major culprits for liver diseases including hepatitis.
Racemethionine and taurine formulation in Hepatoprotection :
The best way to protect the liver is to provide the basic building blocks to support its functions or to increase the antioxidant defence that protects the liver cells against toxic damages. Certain amino acids have found to play important role in these vital functions, racemethionine and Taurine are the two major amongst them.
H
-C—N
HO
CH2
?H2
S
j
CH3
Racemethionine:
The role of racemethionine, sulfur containing lipotropic amino acid in hepatoprotection has been amply supported. It is a potent methyl donor, powerful antioxidant and a major source of other liver detoxificants including glutathione and S-Adenosyl Methionine (SAMe). Further methionine is the precursor for the synthesis of cysteine and taurine required in large quantities for liver functions.
Racemethionine has following important functions:
- Lipotropic action- This encourages the export of fat from the liver and thus reduces the chances of fatty liver and liver cirrhosis.
- Liver detoxification-
Methionine acts as a chelator, binding to heavy metals such as lead and others and removing them from the body before they can build up and cause damage to tissues. Methionine also protects liver from the damaging effects of drugs like acetaminophen, nimesulide and other hapatotoxic drugs.
Antioxidant
Methionine reconstitutes an important antioxidant defence mechanism. It neutralizes a variety of oxidants by forming methionine sulfoxide and thus scavenges free radicals like H202, superoxide, ozone, hypochlorous acid, and chloramines,
Methionine in Alcoholic liver disorders -
Alcohol is a major cause of liver disease that disrupts methionine and oxidative balance. Methionine supplementation was found to improve the alcohol-induced histological changes in the liver. Triglyceride content of the liver was found to decrease in a dose-dependent manner with increasing methionine ingestion. Hepatic adenosine triphosphate content increased significantly with higher methionine consumption. These results underscore the impairment of the transmethylation/transsulfuration pathway in the development of alcohol-induced liver diseases and the protective role of racemethionine against alcohol induced hepatotoxicities.
Methionine is the major precursor for other important antioxidant substances like SAMe, cysteine and glutathione.
S-adenosyl-L-methiottine (SAM, or SAMe) in liver protection -
SAMe improves and normalizes liver function. In Europe, SAMe is used in the treatment of cirrhosis and liver damage caused by alcohol.
Through methylation, SAMe increases membrane fluidity, restoring several factors that promote bile flow.
Treatment with SAMe helps decrease serum bilirubin (pigment in the blood that can cause jaundice) in patients with elevated serum bilirubin level.
SAMe was also shown to be useful for opposing the oxidative stress and the alcohol-induced liver injury.
Glutathione (GSH) - The Master Antioxidant in liver:
Glutathione is an antioxidant often referred to as the body's "master antioxidant" due to its central role in protecting the body's cells from free radical damage. Glutathione is composed of the amino acids cysteine (formed from methionine), glutamine and glycine and is concentrated in the liver.
Due to its -SH group, glutathione controls many redox reactions. In liver cells, glutathione protects hepatOcytes from the damaging effects of free radicals, toxins, heavy metals and hepatotoxic drugs.
The effect of glutathione depletion in liver is associated with abnormal and elevated liver enzyme like SGOT and SGPT.
Glutathione is important in the management of patients with alcoholic liver disease and viral hepatitis, particularly those with hepatitis C.
Glutathione protects cells in several ways. It neutralizes oxygen molecules before tney can harm cells. It forms the enzyme glutathione peroxidase which neutralizes hydrogen peroxide. It is also a component of another antioxidant enzyme, glutathione-S-transferase which is a broad-spectrum liver-detoxifying enzyme.
Taurine:
Taurine (2-aminoethanesulfonic acid) is a sulfur-containing conditionally-essential amino acid. Derived from methionine and cysteine metabolism, taurine is known to play an important role in numerous physiological functions. Apart from conjugation of bile acids, other metabolic actions of taurine include: detoxification, membrane stabilization, osmoregulation, and modulation of cellular calcium levels. It is found in high concentrations in skeletal muscles, central nervous system as well as in the heart muscles and liver.
Taurine is incorporated into one of the most abundant bile acids, chenodeoxychloic acid. Studies have shown that taurine deficiency results in reduced bile acid secretion, reduced fat absorption and reduced liver function, all of which can be reversed by supplementing the diet with taurine.
Detoxifying effects -Taurine directly combines with toxic molecules and removes them from blood circulation. Thus it helps in blood purification that protects important organs including liver from damages.
Taurine in inflammatory liver cells has cytoprotective action. Taurine increases the activities of antioxidant enzymes like superoxide dismutase, glutathione peroxidase and catalase. Taurine reduces Reactive Oxygen Species (ROS) levels by increasing the levels of the antioxidant enzymes.
Taurine is effective in removing fatty liver deposits, preventing liver disease, and reducing cirrhosis. Importantly taurine has protective and preventive role in portal hypertension, the major cause of death in cirrhotic liver conditions.
During hepatitis, taurine supplementation has been shown to reduce bilirubin, total bile acids, and biliary glycine taurine ratio which are important indicators of liver toxicities.
Taurine plays important role in alcoholic liver disorders. Taurine reverses the hepatic steatosis (deposition of fat) and lipid peroxidation caused by chronic alcohol consumption.
Racemethionine + Taurine: A synergistic combination -
Both Racemethionine and Taurine are concentrated in liver and play important role in liver function, detoxification of harmful substances and hepatocyte protection. Many of their functions are independent of each other.
When taurine is used up for metabolic reactions, it is biosynthesized from methionine. Thus methionine is used up in this process and can become deficient in cells during increased workload. Supplementation of taurine reduces the need for conversion of methionine to taurine thus allowing Methionine for its other important functions of liver protection.
Further, in some patients excess methionine has been reported to increase homocysteine levels. It is found that taurine causes excretion of homocysteine via kidney and thus balances the effect on homocysteine, if any.
Thus the combination of racemethionine and Taurine is a synergistic combination useful in various liver diseases and others.
Conclusion:
Few patients have responded well with formulation in hepatic disorders of various etiologists. Clinically and pathologically liver function tests were in normal range after the drug administration.
Claims
1. A synergistic combination of taurine and racemethionine an effective amount for treating liver diseases comprising, taurine taken in the range of 250mg to 500mg, and recemethionine taken in the range of lOOmg to 200mg, along with excipients selected from maize starch 50 mg to 75mg, lactose 44mg to 66mg, microcrystalline cellulose 60mg to 90mg, colloidal silicone dioxide lOmg to 15mg, poly vinyl pyrrolidine 12mg to 18mg, isopropyl alcohol 90mg to 135mg, sodium starch glycolate 5mg to 7.5 mg , crosspovidene4mg to 6mg, magnesium stearate lOmg to 15mg, purified talc 5 mg to 7. 5mg, hydroxypropyl methyl cellulose l lmg , titanium dioxide 2, isopropyl alcohol 97mg, methylene chloride 146mg, Sucrose SOOrrtg to 750mg, Sorbitol 2000mg to 3250mg, Citric acid 5mg to 7.5mg, SMP 5mg to 7.5mg, SPP lmg to 7.5mg, Bronopol 1.25mg to 2.50mg, Citric acid 1.25mg to 2.50mg, Sodium CMC lOmg to 35mg, Sodium benzoate lOmg to 35mg, Water, Colour & essence.
2. A pharmaceutical process as claimed in claim 1, wherein the pharmaceutical composition for the tablet is that taurine taken in amount of 450mg, and recemethionine taken I80mg, excipients taken in an amount of maize starch 55mg, lactose 48.5mg, microcrystalline cellulose 66mgj colloidal silicone dioxidel lmg, poly vinyl pyrrolidine I3.2mg, isopropyl alcohol 99mg, sodium starch glycolate 5,5 mg , Crossprovidone 4.4mg, magnesium stearate l lmg, purified talc5.5mg, hydroxypropyl methyl cellulose l lmg , titanium dioxide 2, isopropyl alcohol 97mg, methylene chloride taken at 146mg,
3. A pharmaceutical process as claimed in claim I, wherein oral formulation comprising the following steps,
a) Dispensing,
• Weigh the active and excipients in a desired quantity.
• All the raw materials are then packed in individual poly bags with dispensing Label
The dispensed materials to be transferred to the dispensing hold followed by transferring to processing area
b) Sifting
Sift separately required quantities of taurine, racemethionine, Maize Starch, Lactose, Microcrystalline Cellulose, Colloidal silicon Dioxide and collect each in a individual double lined polybag. c) Dry mixing
Load the sifted Materials in Rapid Mixer Granulator (RMG) and mix for 15 minutes at 100 RPM. d) Binder preparation
In a Clean S.S. vessel, prepare binder solution with Polyvinyl Pyrrolidone (PVPK-30) and isopropyl Alcohol by continuous stirring until to get uniform Paste. e) Granulation
After Completion of dry mixing, add binder solution in RMG with impeller at 75 RPM and chopper off for 5 minute to prepare granules f) Drying
Air dries the wet mass in fluidized bed dryer for 05 minutes.
Dry material at an inlet air temperature of 60°C ± 5°C.
Rake the material after completion of each drying cycle.
Continue dry the granules till LOD of the granules achieved between NMT 5.0 % w/w at l05°C. g) Sifting and Milling
• Sift the dried granules through sieve 16 # (SS) and collect the granules in cleaned container lined with polybag.
• Mill the oversized Granules retained on sieve through 1.2 mm SS screen with forward direction at 1500 RPM. Collect the milled granules in cleaned container line with polybag.
h) blending and lubricating
• Sift separately Purified Talc, Magnesium Stearate, Sodium Starch Glycolate* and Crossprovidone and through Sieve 60 # and collect in a double lined polybag.
• Transfer the dried sifted and milled granules of above stage in to Octagonal Blender and add above sifted lubricant materials (Sodium Starch Glycolate & Purified Talc, Crossprovidone, Magnesium Stearate) in to octagonal blender. Close the lid of blender and run it for 15 min at 15 RPM.
• Add sifted Magnesium Stearate of above stage to Octagonal blender. Close the lid of blender and run 3 minutes at 15 RPM.
i) Compression
• Compress the lubricated blend using tablet shaped punches by compression machine, j) Coating
Preparation of coating solution
• In S.S. vessel transfer required quantities of Hydroxy Propyl Methyl Cellulose, Titanium Dioxide adds Isopropyl Alcohol, Methylene Chloride with continuous stirring to prepare the slurry.
• Transfer the solution to solution tank and use for coating purpose.
Coatng instruction and operation
• Load the tablets into Pearl Cpater Switch on the hot air blower. Adjust the temperature of incoming air to 50°C- 55°C. Start rotation of coating pan and spray the dispersion.
• Continue coating until entire coating dispersion is used.
• Store the coated Tablets in double Polylined Container with tight fitting lids; label the Containers with all relevant Batch details.
4. A pharmaceutical process as claimed in claim 1, wherein tablet formulation comprising the following steps,
a) Take 450mg taurine shift it 40 # then add in mass mixture.
b) Take 180 racemethionine shift it 40 # then add in mass mixture.
c) Take lactose 48mg shift it 40 # then add in mass mixture.
d) Take starch 5.5mg shift it 40 # then add in mass mixture.
e) Take 99mg I.P.A then adds in mass mixture mix it for 30 minutes.
f) Take P.V.P.K 13.2mg with contains stirring till until clear solution
g) Add step (5) solution slowly in mass mixture with mixing till proper mass obtain. h) Shift above mass through 8# in multi mill.
i) Keep it in tray drayer.
j) Adjust temp at 40° c for 4 hours till I.P.A complete remove then heat it 60° c for two hours.
k) Shift it at 16 # through shifter.
1) Pass magnesium stearate 150 gm and talcum 100 gm mix it and shift it through 100# m) Mix step 11 & 12 in mass mixture for 5 minutes.
5. A pharmaceutical process as claimed in claim 1, wherein capsule formulation comprising the following steps,
a) Take 5 kg and taurine shift it 40 # through shifter.
b) Take 2 kg racemethionine shift it 40 # through shifter.
c) Take Magnesium Stearate 0.030 kg shift it 100 # through shifter.
d) Take talcum 0.020 kg shift it 100 # through shifter.
e) Mix it add material and mixture it for 30 minutes
f) Check cap filling machine.
g) Fill 300 cap plates with cap.
h) Fill it with powder 223gms for 300 cap.
i) In process - Check 300 filled capsule
Proper sealing
Denting
Locking
j) 20 cap individual cap weight limit +/- 3%
k) 20 cap weight limit +/- 2%
1) DT not more than 10 minutes,
m) Polishing
n) Striping
6 A pharmaceutical process as claimed in claim 1, wherein granules formulation comprising the following steps
a) Dispensing
• Weigh the active and excipients-as per requisition.
• All the raw materials are then packed in individual poly bags with dispensing Label and containers with proper status label.
• The dispensed materials to be transferred to the dispensing hold.
• The raw material is then transferred to the processing area when required i.e., when batch manufacturing is undertaken.
b) Sifting:
• Sift separately required quantities of Taurine, Racemethionine, Maize Starch, Lactose, Microcrystalline Cellulose, Colloidal silicon Dioxide and collect each in a individual double lined polybag. c) Dry Mixing
• Load the sifted Materials in Rapid Mixer Granulatof (RMG) and mix for 15 minute at 100 RPM.
d) Binder Preparation
• In a Clean S.S. vessel, prepare binder solution with Polyvinyl Pyrrolidone (PVPK-30) and Isopropyl Alcohol by continuous stirring to get uniform Paste.
e) Granulation
• After Completion of dry mixing, start to add binder solution in RMG with impeller at 75 RPM and chopper off for 5 minute. Stop RMG and rake the stick material on RMG inner wall and Impeller.
• Close the lid of RMG and start mixing speed at 75 RPM and chopper off for 05 minutes to make lumps of resulting materials. Then allow mixing by running impeller at 75 RPM and chopper on for 2 minute to prepare granules.
f) Drying
• Air dry the wet mass in fluidized bed dryer for 05 minutes.
• Dry material at an inlet air temperature of 60°C ± 5°C.
• Rake the material after completion of each drying cycle.
• Continue dry the granules till LOD of the granules achieved between NMT 5.0 % w/w at 105°C.
g) Sifting and Milling
• Sift the dried granules through sieve 16 # (SS) and collect the granules in cleaned container lined with polybag.
• Mill the oversized Granules retained on sieve through 1.2 mm SS screen with forward direction at 1500 RPM. Collect the milled granules in cleaned container line with polybag.
h) Blending and Lubrication:
• Sift separately Purified Talc, Magnesium Stearate, Sodium Starch Glycolate, and Crossprovidone and through Sieve 60 # and collect in a double lined polybag.
• Transfer the dried sifted and milled granules of above stage in to Octagonal Blender and add above sifted lubricant materials (Sodium Starch Glycolate & Purified Talc, Crossprovidone, Magnesium Stearate) in to octagonal blender. Close the lid of blender and run it for 1 min at 15 RPM.
• Add sifted Magnesium Stearate of above stage to octagonal blender. Close the lid of blender and run 3 minutes at 15 RPM.
7 A pharmaceutical process as claimed in claim 1, wherein syrup formulation comprising the following steps
a) Take 20 litres D. M. water heat at 20° C than add sucrose with continuous stirring till complete sucrose dissolve.
b) Add SMP 0 .100 kg, SPP 0.020 kg, sodium banzoate 0.100 kg bfonopol, 0.025kg with continuous CMC sodium 0.200 kg and citric acid 0.100 kg.
c) Then heat it to boil.
d) Add sorbitol 20 litters with stirring.
e) Fill it then keep it at room temperature.
f) Dissolve L- Taurine 6.750kg in DM water stirring till complete dissolve then filter it and add it in main tank.
g) Dissolve racemethionine 2.500kg in 10 litter DM water stirring till complete dissolve then filter it and add it in main tank.
h) Dissolve colour tetrazine yellow 10 gm in 5 litter DM water stirring till complete dissolve then filter it and add it in main tank.
i) Dissolve essence chocolate bourbon 300 ml and essence vanilla 30 ml and essence honey 20 ml mix it and add in main tank.
j) Complete volume 100 litter by adding DM water,
k) Adjust pH 4.00 to 5.00.
1) Filter Complete volume and keep it with label. Ready for filling.
8 A pharmaceutical composition as claimed in claim 1 wherein it is available in various oral dosages forms such as tablet, capsule, granules and syrup thereof.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201691599A EA201691599A1 (en) | 2014-05-19 | 2014-08-01 | COMBINATION OF TAURINE AND RACEMETIONINE FOR THE TREATMENT OF LIVER DISEASES |
| AP2016009662A AP2016009662A0 (en) | 2014-05-19 | 2014-08-01 | Combination of taurine and racemethionine for treatment of liver diseases |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1668MU2014 | 2014-05-19 | ||
| IN1668/MUM/2014 | 2014-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015177805A1 true WO2015177805A1 (en) | 2015-11-26 |
Family
ID=51903973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2014/000510 WO2015177805A1 (en) | 2014-05-19 | 2014-08-01 | Combination of taurine and racemethionine for treatment of liver diseases |
Country Status (3)
| Country | Link |
|---|---|
| AP (1) | AP2016009662A0 (en) |
| EA (1) | EA201691599A1 (en) |
| WO (1) | WO2015177805A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817695A (en) | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
| WO2005002592A2 (en) * | 2003-07-01 | 2005-01-13 | Ranbaxy Laboratories Limited | Stable oral compositions of azithromycin monohydrate |
| WO2006062273A1 (en) | 2004-12-10 | 2006-06-15 | Se-Gyu Kim | Branched-amino acid supplement food |
| WO2011045810A1 (en) * | 2009-08-13 | 2011-04-21 | Zota Health Care Limited | Pharmaceutical compositions containing taurine and race-methionine for the treatment of alcoholism |
| WO2013124860A1 (en) * | 2012-02-23 | 2013-08-29 | Zota Health Care Ltd | Potent revital formulation |
-
2014
- 2014-08-01 AP AP2016009662A patent/AP2016009662A0/en unknown
- 2014-08-01 WO PCT/IN2014/000510 patent/WO2015177805A1/en active Application Filing
- 2014-08-01 EA EA201691599A patent/EA201691599A1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817695A (en) | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
| WO2005002592A2 (en) * | 2003-07-01 | 2005-01-13 | Ranbaxy Laboratories Limited | Stable oral compositions of azithromycin monohydrate |
| WO2006062273A1 (en) | 2004-12-10 | 2006-06-15 | Se-Gyu Kim | Branched-amino acid supplement food |
| WO2011045810A1 (en) * | 2009-08-13 | 2011-04-21 | Zota Health Care Limited | Pharmaceutical compositions containing taurine and race-methionine for the treatment of alcoholism |
| WO2013124860A1 (en) * | 2012-02-23 | 2013-08-29 | Zota Health Care Ltd | Potent revital formulation |
Also Published As
| Publication number | Publication date |
|---|---|
| AP2016009662A0 (en) | 2016-12-31 |
| EA201691599A1 (en) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hassan et al. | Ameliorating effect of chicory (Cichorium intybus L.)-supplemented diet against nitrosamine precursors-induced liver injury and oxidative stress in male rats | |
| US20090142410A1 (en) | Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise | |
| CN102626225B (en) | Health food having functions of bone density increasing and joint protecting, and preparation method thereof | |
| CN108835638A (en) | A kind of Soboring-up liver-protecting improves the food and preparation method thereof of immunity | |
| US20250090546A1 (en) | Chlorophyll composition | |
| WO2014038630A1 (en) | Cesium-excreting agent, poisonous metal-excreting agent, food or beverage, feed, and medicinal product | |
| Bawono et al. | The role of catechins of Camellia sinensis leaves in modulating antioxidant enzymes: A review and case study | |
| CN100467038C (en) | Biological and pharmacological effects of a liver-protecting preparation containing multiple vitamins and its preparation method | |
| Klatz | The Official Anti-Aging Revolution: Stop the Clock Time is on Your Side for a Younger, Stronger, Happier You | |
| WO2015177805A1 (en) | Combination of taurine and racemethionine for treatment of liver diseases | |
| El Kutry | Potential protection effect of using honey, ginger, and turmeric as a natural treatment against chemotherapy of intestinal toxicity | |
| Ojo et al. | Effects of pre-induction administration of Allium sativum on some biochemical parameters in alloxan induced diabetic rats | |
| JP4355967B2 (en) | Pharmaceutical composition | |
| Hassan | Effect of dietary supplementation with tigernut tubers on streptozotocin-induced diabetic rats | |
| CN109663123B (en) | Capsule for improving liver injury and body fatigue and preparation method thereof | |
| Todorović et al. | Roles of sulfur-containing amino acids in gastrointestinal physiology and pathophysiology | |
| EA041245B1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING TAURINE AND RACEMETIONINE FOR THE TREATMENT OF LIVER DISEASES | |
| JP2005126379A (en) | New synergetic composition of vitamins, minerals and trace element for stimulating elimination of intracellular lipid deposit | |
| Khandelwal et al. | Evaluation of Ezenus in an experimental model of diet-induced alcoholic and non-alcoholic fatty liver condition in rats | |
| KR101342489B1 (en) | Composition for liver protection containing the extract of ixeris dentata leaf | |
| اسحق et al. | Evaluation of Therapeutic Effect of Cantaloupe, Grape and Pumpkin Seeds on Cisplatin Induced Nephrotoxicity in Rats | |
| Ray et al. | Long term exposure effect of a unique metabolic nutrition system containing a diverse group of phytochemicals on serum chemistry and genomic and non‐genomic changes in the liver of female B6C3F1 mice | |
| O'Byrne-Navia et al. | Orthomolecular parenteral nutrition therapy | |
| WO2013124860A1 (en) | Potent revital formulation | |
| CN106690123A (en) | Jelly fish product and application of jelly fish in preparing product for promoting human body to remove aluminum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14799556 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 201691599 Country of ref document: EA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14799556 Country of ref document: EP Kind code of ref document: A1 |